EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old

Patricia Winokur iD, Oyeniyi Diya, David Fitz-Patrick, Michael Dever, Juleen Gayed, Stephen Lockhart, Xia Xu, Ying Zhang, Vishva Bangad, L Tyler Wadsworth, Kevin Cannon, Jose F Cardona iD und 16 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag026 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Patricia Winokur und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, SARS-CoV-2, Immunogenicity, Vaccine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BioNTech, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emergence of severe acute respiratory syndrome coronavirus 2 sublineages warrants the use of sequence-adapted vaccines to provide protection against coronavirus disease 2019.

Methods

In this phase 3 trial, adults 18‒55 years old who had previously received three 30 μg doses of BNT162b2 vaccine were randomized to receive a 60 or 30 μg dose of bivalent Omicron BA.1‒adapted BNT162b2 comprising equal amounts of ancestral and monovalent messenger RNA BA.1 (bivalent BA.1) or a 60 μg dose of monovalent Omicron BA.1‒adapted BNT162b2 (monovalent BA.1). Safety (local reactions, systemic events, adverse events [AEs], and serious AEs) was the primary objective. Exploratory analyses assessed immune responses against Omicron BA.1, BA.4, and BA.5 subvariants and ancestral strain.

Results

Among the 1054 randomized participants who received monovalent BA.1 or bivalent BA.1, frequencies of local reactions, systemic events, and AEs were slightly higher with 60 µg monovalent BA.1 than either bivalent BA.1 dose level. One month after vaccination, bivalent BA.1 (30 and 60 μg) and monovalent BA.1 (60 μg) induced substantial neutralizing responses against Omicron BA.1 (50% neutralizing titer geometric mean fold rises [GMFRs], 15.4 [95% CI 12.4–19.2], 17.1 [13.7–21.4], and 24.6 [19.3–31.4], respectively) and ancestral strain (GMFRs, 6.2 [5.1–7.6], 7.3 [6.0–8.9], and 7.0 [5.7–8.7], respectively). In a smaller (n = 30/treatment arm) sentinel cohort, all study vaccines modestly neutralized Omicron BA.4 and BA.5.

Conclusions

Bivalent and monovalent BA.1‒adapted vaccines had a safety profile similar to the original BNT162b2 30 μg and induced substantial neutralizing responses against Omicron BA.1 and ancestral strains. Clinical Trials Registration NCT04955626.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19SARS-CoV-2Immunogenicity, VaccineHumansFemaleBNT162 VaccineMiddle AgedMaleAdultAntibodies, ViralYoung AdultAdolescentAntibodies, Neutralizing

Stichwörter der Autor:innen

BA.1BNT162b2COVID-19OmicronSARS-CoV-2

Substanzen

COVID-19 VaccinesBNT162 VaccineAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Division of Infectious Diseases, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Vaccine Research and Development, Pfizer Ltd, Hurley, United Kingdom.
  • East-West Medical Research Institute, Honolulu, Hawaii, USA.
  • Clinical Neuroscience Solutions, Orlando, Florida, USA.
  • Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Vaccine Research and Development, Pfizer Inc, Pearl River, NewYork, USA.

ORCID-Profile: Patricia Winokur, Jose F Cardona, Ingrid L Scully, David Cooper, William C Gruber, Nicholas Kitchin

Förderung

  • BioNTech
  • Pfizer

Zitieren

APA

Winokur, P., Diya, O., Fitz-Patrick, D., Dever, M., Gayed, J., Lockhart, S., Xu, X., Zhang, Y., Bangad, V., Wadsworth, L. T., Cannon, K., Cardona, J. F., Usdan, L., Ginis, J., Mensa, F. J., Zou, J., Xie, X., Lu, C., Buitrago, S., …, & Kitchin, N. (2026). Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag026

Vancouver

Winokur P, Diya O, Fitz-Patrick D, Dever M, Gayed J, Lockhart S, et al. Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag026

BibTeX
@article{Winokur2026,
  author = {Winokur, Patricia and Diya, Oyeniyi and Fitz-Patrick, David and Dever, Michael and Gayed, Juleen and Lockhart, Stephen and Xu, Xia and Zhang, Ying and Bangad, Vishva and Wadsworth, L Tyler and Cannon, Kevin and Cardona, Jose F and Usdan, Lisa and Ginis, John and Mensa, Federico J and Zou, Jing and Xie, Xuping and Lu, Claire and Buitrago, Sandra and Scully, Ingrid L and Cooper, David and Koury, Kenneth and Jansen, Kathrin U and Türeci, Özlem and Şahin, Uğur and Swanson, Kena A and Gruber, William C and Kitchin, Nicholas},
  title = {Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag026}
}
Kostenlos starten →